The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy
Open Access
- 1 January 2016
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 12 (1), 39-43
- https://doi.org/10.17925/EE.2016.12.01.39
Abstract
Medullary thyroid cancer (MTC) is a rare cancer comprising approximately 5% of all thyroid cancers. The majority arises sporadically but around 25% are hereditary forming part of the Multiple Endocrine Neoplasia (MEN) type 2 syndromes. The initial management is surgical, the extent of resection determined by radiological stage, presence of and specific REarranged during Transfection (RET) oncogene mutation and level of serum calcitonin. External beam radiotherapy may be utilised in the adjuvant setting to improve local control rates. Conventional cytotoxic agents remain essentially futile in the management of advanced MTC with response rates of around 15–20% at best. Over the last decade, alongside a greater understanding of the molecular pathogenesis of MTC we have seen the development of small molecule agents including tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFRs) and RET with activity in advanced MTC. This review will examine the evidence for this therapeutic approach, when to consider initiating and how to manage toxicities arising from such therapies in the treatment of advanced MTC.Keywords
This publication has 34 references indexed in Scilit:
- Destabilizing RET in targeted treatment of thyroid cancersEndocrine Connections, 2016
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerThe New England Journal of Medicine, 2015
- Mechanisms of RET signaling in cancer: Current and future implications for targeted therapyCellular Signalling, 2014
- Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary RegressionJournal of Clinical Endocrinology & Metabolism, 2011
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid CarcinomaThyroid®, 2010
- RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancerExpert Review of Anticancer Therapy, 2008
- Prognostic Factors in Well-Differentiated Follicular-Derived Carcinoma and Medullary Thyroid CarcinomaThyroid®, 2001
- Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the ThyroidEndocrine Pathology, 2000
- Activation of a novel human transforming gene, ret, by DNA rearrangementCell, 1985